Observational studies link GLP-1 drugs to lower cancer risk

A series of studies presented at the American Society of Clinical Oncology annual meeting in Chicago suggests that widely used GLP-1 medications, such as Ozempic, Wegovy, and Mounjaro, may be associated with a lower risk of developing and dying from several types of cancer. The findings, while preliminary, point to potential benefits beyond the drugs' established roles in managing diabetes and weight.

One of the largest analyses, led by researchers at the University of Pennsylvania, examined health records of more than 110,000 women between the ages of 45 and 80. It found that women who were prescribed GLP-1 drugs had approximately a 30 percent lower likelihood of developing breast cancer compared to those who were not taking the medications. The study's lead author, Dr. Elizabeth McDonald, emphasized that the research was observational and does not confirm a causal relationship, but she said it adds to growing evidence warranting further investigation of these drugs as potential cancer prevention tools.

The apparent benefits extended beyond prevention. A separate Italian study of 27,000 breast cancer patients indicated that adding GLP-1 medications to standard treatment was...